Cosmetic composition for preventing, alleviating, or ameliorating hair loss

Abstract

The present invention relates to a cosmetic composition for preventing, alleviating, or ameliorating hair loss. According to the present invention, provided is a cosmetic composition which not only inhibits the action of TGF-β1 factor, but also has a 5α-reductase inhibitory effect, and thus can exhibit an excellent effect in preventing, alleviating, or ameliorating hair loss.

Description

Cosmetic composition for preventing, alleviating or improving hair loss

[0001] Cross-citation with related applications

[0002] This application claims the benefit of priority to Republic of Korea Patent Application No. 10-2023-0120959, filed September 12, 2023, Republic of Korea Patent Application No. 10-2024-0099301, filed July 26, 2024, and Republic of Korea Patent Application No. 10-2024-0099302, filed July 26, 2024, the entire contents of which are incorporated herein by reference.

[0003]

[0004] The present invention relates to a cosmetic composition that exhibits hair loss prevention, alleviation or improvement effects.

[0005]

[0006] Hair loss occurs due to various factors such as heredity, disease, childbirth, stress, hormones, excessive sebum secretion, poor blood circulation, decreased scalp function, and aging.

[0007] Alopecia generally refers to a condition in which the proportion of hair in the anagen phase decreases and the proportion of hair in the catagen or resting phase increases, resulting in an abnormal increase in the number of hairs that fall out. As hair loss progresses, the anagen phase shortens, the transition to the catagen and resting phases is accelerated, and the volume of the hair papilla decreases, causing the hair follicles to become increasingly smaller. Therefore, to treat alopecia, it is important to accelerate the transition of hair follicles from the telogen phase to the anagen phase and lengthen the shortened anagen phase. In addition, it is crucial to inhibit the action of TGF-β1, a factor that promotes the transition of the anagen phase of hair follicles to the catagen phase.

[0008] Meanwhile, male pattern baldness, which accounts for the largest proportion of hair loss cases, is also called androgenetic alopecia. Androgenetic alopecia occurs when dihydrotestosterone (DHT), produced by the male hormone testosterone and its activating enzyme 5α-reductase, acts on hair follicles to inhibit cell division and hair growth.

[0009] Commercially available hair loss products typically contain effective ingredients that strengthen hair root function, moisturize the scalp, and promote blood flow. However, no product has demonstrated a significant effect on hair loss symptoms. Furthermore, most 5-alpha-reductase inhibitors are steroid-based, which can cause various side effects.

[0010]

[0011] The present invention provides a cosmetic composition for preventing, alleviating or improving hair loss, which comprises a non-steroidal compound as an active ingredient.

[0012] And, the present invention provides a pharmaceutical composition for preventing or treating hair loss, which contains a non-steroidal compound as an active ingredient.

[0013]

[0014] According to one embodiment of the invention, a cosmetic composition for preventing, alleviating or improving hair loss is provided, which comprises 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0015] According to another embodiment of the invention, there is provided a use of 3-hydroxypropionic acid or a derivative thereof for the manufacture of a cosmetic for preventing, alleviating or improving hair loss.

[0016] According to another embodiment of the invention, a method for preventing, alleviating or improving hair loss is provided using a cosmetic composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0017] According to another embodiment of the invention, a pharmaceutical composition for preventing or treating hair loss is provided, comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0018] According to another embodiment of the invention, there is provided a use of 3-hydroxypropionic acid or a derivative thereof for the manufacture of a medicament for preventing or treating hair loss.

[0019] According to another embodiment of the invention, a method for preventing, alleviating or treating hair loss is provided using a pharmaceutical composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0020]

[0021] Hereinafter, the cosmetic composition for preventing, alleviating or improving hair loss and the pharmaceutical composition for preventing or treating hair loss according to an embodiment of the invention will be described in more detail.

[0022]

[0023] The terms and words used in this specification and claims should not be interpreted as limited to their usual or dictionary meanings, but should be interpreted with meanings and concepts that conform to the technical idea of ​​the invention, based on the principle that the inventor can appropriately define the concept of the term to explain his or her own invention in the best way.

[0024] Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting.

[0025] The present invention is susceptible to various modifications and takes various forms. Specific embodiments are illustrated and described in detail below. However, this is not intended to limit the present invention to specific disclosed forms, but rather to encompass all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.

[0026] As used herein, the singular forms also include the plural forms unless the context clearly dictates otherwise.

[0027] As used herein, the term "including" means specifying a particular characteristic, region, integer, step, operation, element and / or component, but does not exclude the presence or addition of other particular characteristics, regions, integers, steps, operations, elements, components and / or groups.

[0028] In this specification, when a temporal relationship is described as, for example, ‘after’, ‘following’, ‘next to’, or ‘before’, it may also include cases where it is not continuous, unless the expression ‘immediately’ or ‘directly’ is used.

[0029] As used herein, the term "hair loss" or "alopecia" means a condition in which hair is absent in areas where hair should normally be present due to abnormal hair loss.

[0030] As used herein, the term "prevention" refers to suppressing the occurrence of symptoms caused by hair loss or its complications. As used herein, the term "alleviation" refers to the alleviation of symptoms caused by hair loss or its complications. Furthermore, the term "improvement" refers to the improvement of symptoms caused by hair loss or its complications.

[0031] The term “treatment” as used herein means alleviation or elimination of symptoms due to hair loss that has already occurred or symptoms due to complications of hair loss.

[0032] In this specification, “derivative” means a compound that has been changed by a reaction such as introduction of a functional group, oxidation, reduction, or substitution of atoms in a parent compound of an organic compound, without significantly changing the structure and properties of the parent compound.

[0033] And, in the present specification, the term "comprising as an active ingredient" means that the composition according to the embodiment of the invention includes 3-hydroxypropionic acid or a derivative thereof in an amount sufficient to achieve the effect of preventing, treating or improving hair loss.

[0034]

[0035] As a result of the inventors' continued research, it was confirmed that 3-hydroxypropionic acid can be excellent in preventing, alleviating, or improving hair loss.

[0036] In particular, 3-hydroxypropionic acid not only inhibits the action of the TGF-β1 factor, but also has an inhibitory effect on 5α-reductase, so a composition containing 3-hydroxypropionic acid or a derivative thereof as an active ingredient can exhibit excellent effects in preventing, alleviating, and improving hair loss.

[0037]

[0038] According to one embodiment of the invention, a cosmetic composition for preventing, alleviating or improving hair loss is provided, which comprises 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0039]

[0040] The above cosmetic composition for preventing, alleviating, or improving hair loss comprises 3-hydroxypropionic acid or a derivative thereof as an active ingredient. Preferably, the cosmetic composition for preventing, alleviating, or improving hair loss comprises 3-hydroxypropionic acid as an active ingredient.

[0041]

[0042] 3-Hydroxypropionic acid can be applied as an active ingredient by being synthesized by chemical or biological methods.

[0043] According to one embodiment, 3-hydroxypropionic acid obtained through a biological process such as fermentation of a strain having 3-hydroxypropionic acid production ability may be preferably used as the effective ingredient. 3-hydroxypropionic acid obtained by the above method is radioactive carbon isotope ( 14 C) may be included.

[0044] Preferably, the active ingredient may have a radioactive carbon isotope content of 20 pMC (percent modern carbon) or more as measured by ASTM D6866-21, and a biocarbon content of 20 wt% or more. Specifically, the active ingredient may have a radioactive carbon isotope content of 20 pMC or more as measured by ASTM D6866-21, or 50 pMC or more, or 90 pMC or more, or 100 pMC or more, or 90 to 110 pMC; and a biocarbon content of 20 wt% or more, or 50 wt% or more, or 80 wt% or more, or 90 wt% or more, or 95 wt% or more, or 90 to 100 wt%.

[0045] The above radiocarbon isotope content (pMC) is the radiocarbon isotope contained in 3-hydroxypropionic acid ( 14 C) and radiocarbon isotopes of modern reference materials ( 14 C) refers to the ratio of radiocarbon isotope content. Note that the effects of the nuclear testing program in the 1950s are still ongoing and have not been dissipated, so the radioactive carbon isotope content (pMC) may be greater than 100%.

[0046] The above biocarbon content represents the content of biocarbon relative to the total carbon content contained in 3-hydroxypropionic acid, and a larger value may indicate that the compound is more environmentally friendly.

[0047] If the content of radioactive carbon isotopes (pMC) and biocarbon content of the above 3-hydroxypropionic acid is too low, the environmental friendliness is reduced and it may not be considered as a bio-derived material.

[0048] Radioactive carbon isotopes ( 14 C) 1X10 carbon atoms in the Earth's atmosphere 12 It is about 1 per 100, has a half-life of about 5700 years, and is oxidized by cosmic rays and ordinary nitrogen ( 14 N) can be abundant in the upper atmosphere due to nuclear reactions involving it.

[0049] Fossil fuels contain radioactive carbon isotopes that have decayed long ago. 14 The C ratio can be virtually zero. When using bio-derived materials as a raw material for 3-hydroxypropionic acid, or when using fossil fuels in combination with them, the content of radiocarbon isotopes (pMC) and biocarbon content in 3-hydroxypropionic acid can be measured using ASTM D6866-21.

[0050] The measurement method can be, for example, by making the carbon atoms contained in the target compound into the form of graphite or carbon dioxide gas and measuring them using a mass spectrometer, or by measuring them according to liquid scintillation spectrometry. In this case, 14 C ion 12 An accelerator can be used to separate the C ions, and the two isotopes can be separated and their contents and content ratios can be measured using a mass spectrometer.

[0051]

[0052] The above cosmetic composition can inhibit the action of the TGF-β1 factor secreted from hair follicle cells by the action of the above active ingredient. Accordingly, the cosmetic composition can exhibit the effect of preventing, alleviating, or improving hair loss by inhibiting the promotion of the growth phase of hair follicles into the catagen phase.

[0053] Additionally, the cosmetic composition can inhibit the activity of 5α-reductase, which produces dihydrotestosterone, through the action of the active ingredient. Accordingly, the cosmetic composition can exhibit the effect of preventing, alleviating, or improving hair loss by inhibiting cell division in hair follicles and preventing the production of dihydrotestosterone, which inhibits hair growth.

[0054]

[0055] According to one embodiment, the cosmetic composition may contain 0.01 wt% to 1.5 wt% of the active ingredient based on the total weight of the cosmetic composition.

[0056] Specifically, the cosmetic composition may contain the effective ingredient in an amount of 0.01 wt% or more, or 0.012 wt% or more, and 1.5 wt% or less, or 1.25 wt% or less, or 1.1 wt% or less, or 1.0 wt% or less, based on the total weight of the cosmetic composition.

[0057] In order to sufficiently achieve the hair loss prevention, alleviation or improvement effect by the action of the above-mentioned effective ingredient, it is preferable that the above-mentioned cosmetic composition contains 0.01 wt% or more or 0.012 wt% or more of the above-mentioned effective ingredient.

[0058] However, if the above-mentioned effective ingredient is included in an excessive amount, the hair loss prevention, alleviation, or improvement effect may be reduced, or side effects such as cytotoxicity may occur. Therefore, it is preferable that the above-mentioned cosmetic composition include the above-mentioned effective ingredient in an amount of 1.5 wt% or less, or 1.25 wt% or less, or 1.1 wt% or less, or 1.0 wt% or less.

[0059] Preferably, the cosmetic composition may contain the effective ingredient in an amount of 0.01 wt% to 1.5 wt%, or 0.01 wt% to 1.25 wt%, or 0.01 wt% to 1.1 wt%, or 0.01 wt% to 1.0 wt%, or 0.012 wt% to 1.0 wt%, based on the total weight of the cosmetic composition.

[0060]

[0061] According to one embodiment, the cosmetic composition may have a cosmetic formulation conventional in the art to which the present invention pertains. For example, the cosmetic composition may be formulated as a solution, emulsion, suspension, paste, gel, cream, lotion, powder, soap, cleansing agent containing a surfactant, oil, powder foundation, emulsion foundation, wax foundation, spray, etc.

[0062]

[0063] The cosmetic composition may further comprise a physiologically acceptable medium comprising water or a mixture of water and an organic solvent.

[0064] For example, the organic solvent may be applied as a lower alcohol having C1-C4 such as acetone, ethanol, and isopropyl alcohol, an alkylene glycol such as ethylene glycol and propylene glycol, ethylene glycol monomethyl ether, monoethyl ether, monobutyl ether, propylene glycol, etc. The physiologically acceptable medium may be applied in an amount of 1 to 90 wt% based on the total weight of the cosmetic composition.

[0065] The above medium can be thickened using a thickener commonly used in the cosmetics or pharmaceutical industries. The thickener can be applied in an amount of 0.1 to 5 wt% based on the total weight of the composition.

[0066] Additionally, depending on the various embodiments of the cosmetic composition, a person skilled in the art can select excipients generally required for preparing such compositions. For example, excipients may include preservatives, stabilizers, pH regulators, osmotic pressure modifiers, emulsifiers, sunscreens, antioxidants, fragrances, dyes, anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants.

[0067]

[0068] According to one embodiment, when the formulation of the cosmetic composition is a powder or spray, it may include a carrier component such as lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc.

[0069] According to one embodiment, when the formulation of the cosmetic composition is a paste, gel, or cream, it may include a carrier component such as animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc.

[0070] In one embodiment, when the formulation of the cosmetic composition is a solution or emulsion, it may include a carrier component such as a solvent, a solubilizer, or an emulsifier. For example, the formulation of the solution or emulsion may include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.

[0071] According to one embodiment, when the formulation of the cosmetic composition is a suspension, a liquid diluent such as water, ethanol or propylene glycol; a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester; microcrystalline cellulose, aluminum metahydroxide, bentonite, etc. may be applied.

[0072] According to one embodiment, when the formulation of the cosmetic composition is a cleansing agent containing a surfactant, it may include a carrier component such as an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, sodium methyl cocoyl taurate, sodium lauroyl sarcosinate, a fatty acid amide ether sulfate, an alkylamidobetaine, a fatty alcohol, a fatty acid glyceride, a fatty acid diethanolamide, a vegetable oil, a lanolin derivative, an ethoxylated glycerol fatty acid ester, and the like.

[0073]

[0074] According to one embodiment, the cosmetic composition may be for hair or scalp.

[0075] For example, the cosmetic composition may have a formulation that is a hair shampoo, hair rinse, hair tonic, hair treatment, scalp treatment, hair lotion, hair cream, hair spray, hair foam, hair gel, hair pack, hair aerosol, hair dye, balm, powder, solid soap, or liquid soap.

[0076]

[0077] According to another embodiment of the invention, there is provided a use of 3-hydroxypropionic acid or a derivative thereof for the manufacture of a cosmetic for preventing, alleviating or improving hair loss.

[0078] Preferably, the use of 3-hydroxypropionic acid or a derivative thereof for the preparation of a cosmetic composition for preventing, alleviating or improving hair loss as described above is provided.

[0079] 3-Hydroxypropionic acid inhibits the action of TGF-β1 factor and has an inhibitory effect on 5α-reductase, so a cosmetic composition containing 3-hydroxypropionic acid or a derivative thereof as an active ingredient can be used for the purpose of preventing, alleviating or improving hair loss.

[0080] In the above use, the active ingredient 3-hydroxypropionic acid or a derivative thereof can be used in an amount of 0.01 wt% to 1.5 wt% based on the total weight of the cosmetic composition.

[0081] In order to sufficiently achieve the effect of preventing, alleviating, or improving hair loss by the action of the above-mentioned effective ingredient, the above-mentioned effective ingredient is preferably used in an amount of 0.01 wt% or more or 0.012 wt% or more based on the total weight of the cosmetic composition. However, if the above-mentioned effective ingredient is used in an excessive amount, the above-mentioned effect may be reduced or side effects such as cytotoxicity may occur. Therefore, the above-mentioned effective ingredient is preferably used in an amount of 1.5 wt% or less, or 1.25 wt% or less, or 1.1 wt% or less, or 1.0 wt% or less based on the total weight of the cosmetic composition. Preferably, the effective ingredient may be used in an amount of 0.01 wt% to 1.5 wt%, or 0.01 wt% to 1.25 wt%, or 0.01 wt% to 1.1 wt%, or 0.01 wt% to 1.0 wt%, or 0.012 wt% to 1.0 wt% based on the total weight of the cosmetic composition.

[0082]

[0083] According to another embodiment of the invention, a method for preventing, alleviating, or improving hair loss is provided using a cosmetic composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient. Specifically, a method for inhibiting the action of a TGF-β1 factor secreted from hair follicle cells using a cosmetic composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient is provided. In addition, a method for inhibiting the activity of 5α-reductase, which produces dihydrotestosterone, using a cosmetic composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient is provided.

[0084] Preferably, the method for preventing, alleviating, or improving hair loss can be performed using the above-described cosmetic composition for preventing, alleviating, or improving hair loss. The method can be performed for 1 to 6 months, 1 to 7 days a week, with an application frequency of 1 to several times a day (for example, 1 to 5 times or 1 to 3 times). The method can be performed by applying the cosmetic composition to a part of the human body (for example, hair or scalp) where prevention, alleviation, or improvement of hair loss is desired. Specifically, the method can be a method for washing hair using the cosmetic composition in a hair shampoo formulation, a method for washing or massaging the scalp using the cosmetic composition in a scalp treatment formulation, or a method for applying the cosmetic composition in a balm formulation to the scalp.

[0085]

[0086] According to another embodiment of the invention, a pharmaceutical composition for preventing or treating hair loss is provided, comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0087] As a result of the inventors' continued research, it was confirmed that 3-hydroxypropionic acid can be excellent in preventing and treating hair loss.

[0088] In particular, 3-hydroxypropionic acid not only inhibits the action of the TGF-β1 factor, but also has an inhibitory effect on 5α-reductase, so a composition containing 3-hydroxypropionic acid or a derivative thereof as an active ingredient can exhibit excellent effects in preventing and treating hair loss.

[0089] The pharmaceutical composition for preventing or treating hair loss comprises 3-hydroxypropionic acid or a derivative thereof as an active ingredient. Preferably, the pharmaceutical composition for preventing or treating hair loss comprises 3-hydroxypropionic acid as an active ingredient.

[0090]

[0091] 3-Hydroxypropionic acid can be applied as an active ingredient by being synthesized by chemical or biological methods.

[0092] According to one embodiment, 3-hydroxypropionic acid obtained through a biological process such as fermentation of a strain having 3-hydroxypropionic acid production ability may be preferably used as the effective ingredient. 3-hydroxypropionic acid obtained by the above method is radioactive carbon isotope ( 14 C) may be included.

[0093] Preferably, the active ingredient may have a radioactive carbon isotope content of 20 pMC (percent modern carbon) or more as measured by ASTM D6866-21, and a biocarbon content of 20 wt% or more. Specifically, the active ingredient may have a radioactive carbon isotope content of 20 pMC or more as measured by ASTM D6866-21, or 50 pMC or more, or 90 pMC or more, or 100 pMC or more, or 90 to 110 pMC; and a biocarbon content of 20 wt% or more, or 50 wt% or more, or 80 wt% or more, or 90 wt% or more, or 95 wt% or more, or 90 to 100 wt%.

[0094]

[0095] The pharmaceutical composition for preventing or treating hair loss can inhibit the action of the TGF-β1 factor secreted from hair follicle cells by the action of the active ingredient. Accordingly, the pharmaceutical composition can exhibit a preventive or therapeutic effect on hair loss by inhibiting the promotion of the growth phase of hair follicles into the catagen phase.

[0096] In addition, the pharmaceutical composition for preventing or treating hair loss can inhibit the activity of 5α-reductase, which produces dihydrotestosterone, through the action of the active ingredient. Accordingly, the pharmaceutical composition can exhibit a preventive or therapeutic effect on hair loss by inhibiting cell division in hair follicles and preventing the production of dihydrotestosterone, which inhibits hair growth.

[0097]

[0098] According to one embodiment, the pharmaceutical composition may comprise 0.01 wt% to 1.5 wt% of the active ingredient based on the total weight of the pharmaceutical composition.

[0099] Specifically, the pharmaceutical composition may contain the active ingredient in an amount of 0.01 wt% or more, or 0.012 wt% or more, and 1.5 wt% or less, or 1.25 wt% or less, or 1.1 wt% or less, or 1.0 wt% or less, based on the total weight of the pharmaceutical composition.

[0100] In order to ensure that the hair loss prevention or treatment effect can be sufficiently achieved by the action of the above-mentioned effective ingredient, it is preferable that the above-mentioned pharmaceutical composition contains 0.01 wt% or more or 0.012 wt% or more of the above-mentioned effective ingredient.

[0101] However, if the above-mentioned effective ingredient is included in an excessive amount, the hair loss prevention or treatment effect may be reduced or side effects such as cytotoxicity may occur. Therefore, it is preferable that the above-mentioned pharmaceutical composition include the above-mentioned effective ingredient in an amount of 1.5 wt% or less, or 1.25 wt% or less, or 1.1 wt% or less, or 1.0 wt% or less.

[0102] Preferably, the pharmaceutical composition may contain the active ingredient in an amount of 0.01 wt% to 1.5 wt%, or 0.01 wt% to 1.25 wt%, or 0.01 wt% to 1.1 wt%, or 0.01 wt% to 1.0 wt%, or 0.012 wt% to 1.0 wt%, based on the total weight of the composition.

[0103]

[0104] The pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.

[0105] Any carrier commonly used in the formulation of pharmaceutical compositions may be used without particular limitation. For example, the carrier may be sucrose, sorbitol, mannitol, lactose, dextrose, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, propyl 4-hydroxybenzoate, talc, magnesium stearate, mineral oil, etc. Pharmaceutically acceptable carriers and formulations are described in detail in Remington's The Science and Practice of Pharmacy (23rd Edition, 2020).

[0106]

[0107] The above pharmaceutical composition may be administered orally or parenterally. When administered parenterally, methods such as skin application, subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, and transdermal administration may be used.

[0108] The appropriate dosage of the above pharmaceutical composition can be determined by comprehensively considering factors such as the patient's age, weight, sex, formulation method, administration method, administration time, etc.

[0109] The pharmaceutical composition may be formulated using a pharmaceutically acceptable carrier and / or excipient. The formulation of the pharmaceutical composition may be a solution, suspension, emulsion, ointment, powder, granule, tablet, or capsule in an aqueous medium or oil.

[0110]

[0111] According to another embodiment of the invention, there is provided a use of 3-hydroxypropionic acid or a derivative thereof for the manufacture of a medicament for preventing or treating hair loss.

[0112] Preferably, the use of 3-hydroxypropionic acid or a derivative thereof for the preparation of a pharmaceutical composition for preventing or treating hair loss as described above is provided.

[0113] 3-Hydroxypropionic acid inhibits the action of TGF-β1 factor and has an inhibitory effect on 5α-reductase, so a composition containing 3-hydroxypropionic acid or a derivative thereof as an active ingredient can be used for the prevention or treatment of hair loss.

[0114] In the above use, the active ingredient, 3-hydroxypropionic acid or a derivative thereof, can be used in an amount of 0.01 wt% to 1.5 wt% based on the total weight of the pharmaceutical composition.

[0115] In order to sufficiently achieve the effect of preventing or treating hair loss by the action of the above-mentioned effective ingredient, the above-mentioned effective ingredient is preferably used in an amount of 0.01 wt% or more or 0.012 wt% or more based on the total weight of the pharmaceutical composition. However, if the above-mentioned effective ingredient is used in an excessive amount, the above-mentioned effect may be reduced or side effects such as cytotoxicity may occur. Therefore, the above-mentioned effective ingredient is preferably used in an amount of 1.5 wt% or less, or 1.25 wt% or less, or 1.1 wt% or less, or 1.0 wt% or less based on the total weight of the pharmaceutical composition. Preferably, the effective ingredient may be used in an amount of 0.01 wt% to 1.5 wt%, or 0.01 wt% to 1.25 wt%, or 0.01 wt% to 1.1 wt%, or 0.01 wt% to 1.0 wt%, or 0.012 wt% to 1.0 wt% based on the total weight of the pharmaceutical composition.

[0116]

[0117] According to another embodiment of the invention, a method for preventing or treating hair loss is provided using a pharmaceutical composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient. Specifically, a method for inhibiting the action of a TGF-β1 factor secreted from hair follicle cells using a pharmaceutical composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient is provided. In addition, a method for inhibiting the activity of 5α-reductase, which produces dihydrotestosterone, using a pharmaceutical composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient is provided.

[0118] Preferably, the method for preventing or treating hair loss can be performed using the pharmaceutical composition for preventing or treating hair loss described above. The method can be performed directly or indirectly on a body part (e.g., the scalp) where hair loss prevention or treatment is required. The method can be performed orally or parenterally. The method can be performed for 1 to 6 months, 1 to 7 days a week, 1 to several times a day (e.g., 1 to 5 times or 1 to 3 times). The method can be performed according to conventional procedures, comprehensively considering factors such as the patient's age, weight, sex, formulation of 3-hydroxypropionic acid or a derivative thereof, administration method, administration time, etc.

[0119]

[0120] According to the present invention, a cosmetic composition that can exhibit an excellent effect in preventing, alleviating or improving hair loss by not only inhibiting the action of the TGF-β1 factor but also having an inhibitory effect on 5α-reductase, and a pharmaceutical composition that can exhibit an excellent effect in preventing or treating hair loss are provided.

[0121]

[0122] Figure 1 is a graph showing the results of evaluating the hair follicle resting phase ratio according to Experimental Example 4.

[0123] Figure 2 is a graph showing the results of evaluating the expression level of hair follicle cell proliferation-related factor proteins according to Experimental Example 4.

[0124]

[0125] The following specific examples of the invention will illustrate its functions and effects in greater detail. However, these examples are provided solely to aid understanding of the invention. The following examples are not intended to limit the scope of the invention in any way, and it will be apparent to those skilled in the art that various modifications and variations are possible within the scope and spirit of the invention.

[0126]

[0127] Manufacturing Example 1

[0128] A recombinant vector was constructed by introducing genes encoding glycerol dehydratase and aldehyde dehydrogenase, which are known to produce 3-hydroxypropionic acid using glycerol as a substrate. The recombinant vector was introduced into the E. coli W3110 strain to construct a strain for producing 3-hydroxypropionic acid.

[0129] Specifically, the BtuR gene encoding adenosyltransferase was cloned into the plasmid pCDF, which contains the gene encoding glycerol dehydratase (dhaB), the gene encoding aldehyde dehydrogenase (aldH), and the gene encoding glycerol dehydratase reactivase (gdrAB), to obtain the pCDF_J23101_dhaB_gdrAB_J23100_aldH_btuR vector. The vector was introduced into the W3110 strain (KCCM 40219) by electroporation using an electroporation device (Bio-Rad, Gene Pulser Xcell), to construct a strain for producing 3-hydroxypropionic acid.

[0130] The above 3-hydroxypropionic acid producing strain was fermented at 35°C in a 5 L fermenter using unpurified glycerol as a carbon source to produce 3-hydroxypropionic acid. To prevent a decrease in pH due to the production of 3-hydroxypropionic acid, calcium hydroxide (Ca(OH)2), an alkali metal salt, was added to maintain the pH at neutral during fermentation.

[0131] After fermentation culture, cells were removed by centrifugation (4000 rpm, 10 min, 4 ℃), and primary purification was performed using activated carbon. The concentration of 3-hydroxypropionic acid in the fermented liquid after the primary purification was 50 to 100 g / L, and it was concentrated to 600 g / L using a rotary evaporator (50 ℃, 50 mbar), and stirred at room temperature (300 rpm) to produce Ca(3HP)2 crystals.

[0132] The crystals were washed three times with ethanol and dried in an oven at 50°C to finally recover them. The weight of the crystals was measured, and the crystals were dissolved in water to obtain 3-hydroxypropionic acid (3HP) using high-performance liquid chromatography (HPLC).

[0133]

[0134] Manufacturing Example 2

[0135] 3-Hydroxypropionic acid (3HP) was obtained in substantially the same manner as in Preparation Example 1, except that Mg(OH)2 was used instead of Ca(OH)2 as the alkali metal salt.

[0136]

[0137] Example 1

[0138] A hair lotion was prepared by mixing 0.025 wt% of 3-hydroxypropionic acid obtained in the above manufacturing example 1, 0.5 wt% of hydroxyethyl cellulose, 2 wt% of cetostearyl alcohol, 2 wt% of stearyl triethyl ammonium chloride, and the remaining amount of purified water (total 100 wt%).

[0139]

[0140] Example 2

[0141] A hair lotion was prepared by mixing 0.05 wt% of 3-hydroxypropionic acid obtained in the above manufacturing example 1, 0.5 wt% of hydroxyethyl cellulose, 2 wt% of cetostearyl alcohol, 2 wt% of stearyl triethyl ammonium chloride, and the remaining amount of purified water (total 100 wt%).

[0142]

[0143] Example 3

[0144] A hair tonic was prepared by mixing 0.0125 wt% of 3-hydroxypropionic acid obtained in the above manufacturing example 1, 55 wt% of ethanol, 3 wt% of glycerin, 5 wt% of castor oil, and the remaining amount of purified water (total 100 wt%).

[0145]

[0146] Example 4

[0147] A hair tonic was prepared by mixing 0.025 wt% of 3-hydroxypropionic acid obtained in the above manufacturing example 1, 55 wt% of ethanol, 3 wt% of glycerin, 5 wt% of castor oil, and the remaining amount of purified water (total 100 wt%).

[0148]

[0149] Example 5

[0150] A hair tonic was prepared by mixing 0.05 wt% of 3-hydroxypropionic acid obtained in the above manufacturing example 1, 55 wt% of ethanol, 3 wt% of glycerin, 5 wt% of castor oil, and the remaining amount of purified water (total 100 wt%).

[0151]

[0152] Example 6

[0153] A pharmaceutical composition in the form of an ointment was prepared by mixing 0.025 wt% of 3-hydroxypropionic acid obtained in the above manufacturing example 1, 0.5 wt% of hydroxyethyl cellulose, 2 wt% of cetostearyl alcohol, 2 wt% of stearyl triethyl ammonium chloride, and the remainder of purified water (total 100 wt%).

[0154]

[0155] Example 7

[0156] A pharmaceutical composition in the form of an ointment was prepared by mixing 0.05 wt% of 3-hydroxypropionic acid obtained in the above manufacturing example 1, 0.5 wt% of hydroxyethyl cellulose, 2 wt% of cetostearyl alcohol, 2 wt% of stearyl triethyl ammonium chloride, and the remainder of purified water (total 100 wt%).

[0157]

[0158] Example 8

[0159] A pharmaceutical composition in the form of an emulsion was prepared by mixing 0.0125 wt% of 3-hydroxypropionic acid obtained in the above manufacturing example 1, 55 wt% of ethanol, 3 wt% of glycerin, 5 wt% of castor oil, and the remaining amount of purified water (total 100 wt%).

[0160]

[0161] Example 9

[0162] A pharmaceutical composition in the form of an emulsion was prepared by mixing 0.025 wt% of 3-hydroxypropionic acid obtained in the above manufacturing example 1, 55 wt% of ethanol, 3 wt% of glycerin, 5 wt% of castor oil, and the remaining amount of purified water (total 100 wt%).

[0163]

[0164] Example 10

[0165] A pharmaceutical composition in the form of an emulsion was prepared by mixing 0.05 wt% of 3-hydroxypropionic acid obtained in the above manufacturing example 1, 55 wt% of ethanol, 3 wt% of glycerin, 5 wt% of castor oil, and the remaining amount of purified water (total 100 wt%).

[0166]

[0167] Experimental Example 1

[0168] (Measurement of radiocarbon isotope and biocarbon content)

[0169] The radiocarbon isotope content (pMC) and biocarbon content of 3-hydroxypropionic acid obtained in Manufacturing Examples 1 and 2 were measured using ASTM D6866-21 (Method B).

[0170] The above biocarbon content refers to the content of biocarbon contained in the 3-hydroxypropionate crystals obtained in the above manufacturing examples 1 and 2, and the radiocarbon isotope ratio (pMC) refers to the radiocarbon isotope contained in the 3-hydroxypropionate crystals ( 14 C) and radiocarbon isotopes of modern reference materials ( 14 C) refers to the ratio.

[0171]

[0172] Concentration (g / L) Radiocarbon isotope ratio (pMC) Biocarbon content (wt%) Manufacturing example 1600 101.52 100 Manufacturing example 2800 102.23 100

[0173] Referring to Table 1 above, it was confirmed that both the 3HP salt crystals of Manufacturing Examples 1 and 2 had a radioactive carbon isotope ratio of 101 pMC or more and a biocarbon content of 100 wt%.

[0174]

[0175] Experimental Example 2

[0176] Human follicle dermal papilla cells (PromoCell GmbH) were cultured in a medium supplemented with fetal calf serum (FCS), bovine pituitary extract (BPE), basic fibroblast growth factor (bFGF), and insulin in a human follicle dermal papilla cells growth medium (PromoCell GmbH) at 37°C under 5% CO2 conditions.

[0177] Cultured human breast papilla cells were seeded in 96-well plates at 5x10 3 The cells were divided into 10 cells, and when cultured to a confluency of 80% or more, they were treated with four different concentrations of 3-hydroxypropionic acid aqueous solution (3HP concentrations of 0 wt%, 0.0125 wt%, 0.025 wt%, and 0.05 wt%) according to Manufacturing Example 1, and then cultured for 24 hours. Afterwards, a WST substrate solution (high sensitivity water soluble tetrazolium salt, CCK-8, DOJINDO) was added to the medium, and cultured at 37°C for 2 hours.

[0178] During culture, the reaction between WST and intracellular dehydrogenase produced insoluble formazan, and its absorbance (OD, wavelength 450 nm) was measured. Cell viability was calculated according to Equation 1 below, and the results are shown in Table 1.

[0179] [Formula 1]

[0180] Cell viability (%) = [ (OD 실험군 - OD 대조군 ) / (OD 음성대조군 - OD 대조군 ) ] X 100

[0181] In the above formula 1, the 'experimental group' is a group treated with an aqueous solution containing 3HP; the 'control group' is a medium containing only WST substrate; and the 'negative control group' is a medium containing WST substrate treated with an aqueous solution containing 0% 3HP.

[0182]

[0183] Human hair papilla cell viability (%) 3HP treatment concentration 0 % (negative control) 0.0125 % 0.025 % 0.05 % 0.1 % 1 time 100.0009 0.84 486.62 486.46 577.5482 times 100.0009 2.03 784.15 386.02 772.7563 times 100.0009 5.06 289.27 585.03 175.694 average 100.0009 2.64 886.68 485.84 175.333 standard deviation 0.0002.174 2.56 10.73 5 2.416 p-value compared to negative control -0.028 0.012 0.001 0.003

[0184] Referring to the above experimental results, a high cell survival rate was observed under the above treatment concentration of 3-hydroxypropionic acid.

[0185]

[0186] Experimental Example 3

[0187] Human follicle dermal papilla cells (PromoCell GmbH) were cultured in a medium supplemented with fetal calf serum (FCS), bovine pituitary extract (BPE), basic fibroblast growth factor (bFGF), and insulin in a human follicle dermal papilla cells growth medium (PromoCell GmbH) at 37°C under 5% CO2 conditions.

[0188] Cultured human breast papilla cells were seeded in 96-well plates at 5x10 4 , and when cultured to more than 80% confluency, 3-hydroxypropionic acid (3HP) according to Manufacturing Example 1 was treated at four concentrations (0 wt%, 0.0125 wt%, 0.025 wt%, 0.05 wt%) and cultured for 24 hours. Afterwards, total RNA within the cells was extracted, and cDNA was synthesized for the extracted RNA. Real-time polymerase chain reaction was performed for the synthesized cDNA. Then, relative quantitative analysis of each gene was performed using GAPDH (one of the house-keeping genes). The relative quantification (RQ) value was calculated according to Equation 2 below.

[0189] [Formula 2]

[0190] RQ = 2 - △△C T

[0191] △△C T = △C T (Treatment) - △C T (Control)

[0192] △C T = C T (Target gene) - C T (Housekeeping gene)

[0193] In the above formula 2, 'Treatment' is a group treated with 3HP; 'Control' is a group not treated with 3HP; 'Target gene' is Srd5α1 and TGF-β1, and 'House-keeping gene' is GAPDH.

[0194]

[0195] 5α-reductase gene expression level (RQ) 3HP treatment concentration 0 % 0.0125 % 0.025 % 0.05 % 1 time 0.98 2 0.85 6 0.87 1 1.32 2 2 times 0.99 2 0.81 5 0.88 0 1.13 3 3 times 1.02 6 0.92 7 0.91 4 1.34 7 average 1.00 0.86 6 0.88 8 1.26 7 standard deviation 0.02 3 0.05 7 0.02 3 0.117 p-value-0.02 8 0.00 0.05 2

[0196] TGF-β1 gene expression level (RQ) 3HP treatment concentration 0 % 0.0125 % 0.025 % 0.05 % 1 time 1.006 0.756 0.704 1.3142 times 1.049 0.864 0.723 1.400 3 times 0.944 0.785 0.655 1.182 average 1.000 0.802 0.694 1.298 standard deviation 0.053 0.056 0.035 0.110 p-value-0.018 0.001 0.012

[0197] Referring to the above experimental results, it was confirmed that the expression of the TGF-β1 gene and the 5α-reductase gene could be significantly suppressed under the treatment concentration of the above 3-hydroxypropionic acid.

[0198]

[0199] Experimental Example 4

[0200] The hair follicle resting phase ratio and the expression level of hair follicle cell proliferation-related factor proteins were evaluated according to the application of 3-hydroxypropionic acid using the following method.

[0201] (1) Tissue culture conditions

[0202] Human hair follicles or scalp tissues (IRB No. 4-2023-1052; Yonsei University College of Medicine, Severance Medical Center Institutional Review Board) provided for research purposes were washed several times with phosphate-buffered saline (PBS) to remove residual impurities and then randomly assigned to each group. Hair follicles and scalp tissues were cultured in Williams' Medium E (Sigma) supplemented with 2 mM L-glutamine (Sigma-Aldrich), 10 μg / ml insulin (Sigma-Aldrich), 100 ng / ml hydrocortisone (Sigma-Aldrich), 0.1% fungizone (Gibco, USA), and 1% antibiotic-antimycotic (Gibco), 1% Penicillin-Streptavidin (Gibco) at 37°C in an incubator with 5% CO2.

[0203] (2) Evaluation of the ratio of hair follicle resting phase

[0204] To induce telogen effluvium in anagen hair follicles, the test composition was treated with 1 μM dihydrotestosterone (DHT). The medium was replaced every 3 days, and the cells were cultured for 6 days. The telogen effluvium ratio was visually assessed by the ratio of telogen effluvium occurring on day 0 to 6 for each hair follicle.

[0205] (3) Evaluation of protein expression levels of cell proliferation-related factors

[0206] After 24 hours of treatment with the test composition on scalp tissue, the obtained tissue was prepared as a frozen block, and frozen sections were cut into 5 μm thick sections using a Cryostat microtome (Leica Biosystems, Germany) and attached onto silane-coated slides. After removing the OCT compound for staining of the tissue sections and photographing the cross-sections, a primary antibody that specifically binds to Ki67 (Anti-Ki67 antibody: ab15580; abcam) was attached, and a fluorescently labeled secondary antibody that specifically binds to this primary antibody (Goat pAb to Rb IgG (H+L): a11012; Invitrogen) was attached. Finally, a fixative (VECTASHIELD) containing blue fluorescent DAPI that stains cell nuclei was used. ® After fixing the tissues with mounting medium with DAPI (Vector laboratories), images were taken at 100x magnification using a fluorescence microscope (M2; Zeiss). The percentage of cells expressing Ki67 among the total cells labeled with DAPI was measured from the images, with a higher value indicating a greater number of cells expressing Ki67.

[0207]

[0208] Telogen ratio (%)Control36.667DHT40.000DHT + 0.1% 3HP6.250DHT + 0.5% 3HP0.000DHT + 1.0% 3HP0.000DHT + 0.5 mM Finasteride0.000DHT + 2 ng / ml Biotin10.000

[0209] Referring to Table 5 and Figure 1 above, in the evaluation of the hair follicle resting phase ratio, it was confirmed that the hair follicle resting phase ratio was significantly reduced when 0.1%, 0.5%, and 1.0% 3HP were applied compared to the DHT control group.

[0210]

[0211] Ki67 positive cells (%)Control14.9340.1% 3HP48.7450.1mM Minoxidil47.1872 ng / ml Biotin44.631

[0212] Referring to Table 6 and Figure 2 above, in the evaluation of hair follicle cell proliferation through Ki67 immunofluorescence staining, it was confirmed that the proliferation effect of hair follicle cells significantly increased when 0.1% 3HP was applied compared to the negative control group.

[0213]

[0214] Formulation Example 1

[0215] A hair tonic is prepared by mixing 0.2 wt% of 3-hydroxypropionic acid according to the above Preparation Example 1, 3.0 wt% of glycerin, 2.0 wt% of butylene glycol, 2.0 wt% of propylene glycol, 0.1 wt% of polyacrylic acid, 0.2 wt% of polyethylene glycol-12 nonylphenyl ether, 0.4 wt% of polysorbate-80, 10.0 wt% of ethanol, 0.1 wt% of triethanolamine, and the remainder of purified water.

[0216]

[0217] Formulation Example 2

[0218] A hair lotion is prepared by mixing 1.0 wt% of 3-hydroxypropionic acid according to Preparation Example 1, 3.0 wt% of glycerin, 3.0 wt% of butylene glycol, 7.0 wt% of liquid paraffin, 7.0 wt% of beta-glucan, 3.0 wt% of caprylic / capric triglyceride, 5.0 wt% of squalene, 1.5 wt% of cetearyl glucoside, 1.2 wt% of polysorbate-60, 0.4 wt% of sorbitan stearate, 0.1 wt% of polyacrylic acid, 0.1 wt% of triethanol amine, and the remainder of purified water.

[0219]

[0220] Formulation Example 3

[0221] A hair shampoo is prepared by mixing 1.0 wt% of 3-hydroxypropionic acid according to the above Preparation Example 1, 0.5 wt% of polyquaternium-10, 10 wt% of sodium lauryl sulfate, 30 wt% of polyoxyethylene lauryl ether, 5 wt% of palm oil fatty acid diethanolamide, 0.5 wt% of citric acid, 0.4 wt% of fragrance, and the remainder of purified water.

[0222]

[0223] Formulation Example 4

[0224] A hair dye is prepared by mixing 1.0 wt% of 3-hydroxypropionic acid according to the above-mentioned manufacturing example 1, 1.0 wt% of dye (Basic Brown 16), 4.5 wt% of benzyl alcohol, 4.0 wt% of glycerin, 5.0 wt% of polyquaternium-6, and the remainder of a cream (a cream containing cetearyl alcohol as a main ingredient).

[0225]

[0226] Formulation Example 5

[0227] A hair treatment is prepared by mixing 1.0 wt% of 3-hydroxypropionic acid according to the above Preparation Example 1, 30 wt% of methylpropanediol, 3 wt% of stearamidopropyl dimethylamine, 2 wt% of dipalmitoylethyl dimonium chloride, 5 wt% of oil, 12 wt% of cetearyl alcohol, and the remainder of purified water.

[0228]

[0229] Formulation Example 6

[0230] A hair spray is prepared by mixing 1.0 wt% of 3-hydroxypropionic acid according to Preparation Example 1, 0.006 wt% of lecithin, 0.12 wt% of amphoteric surfactant, 0.02 wt% of nonionic surfactant, 2.5 wt% of film-forming polymer, 0.005 wt% of cationic polymer, 3.0 wt% of wetting agent, 2.0 wt% of dimethicone, 5.0 wt% of ethanol, 0.5 wt% of pH adjuster, and the remainder of purified water.

[0231]

[0232] Formulation Example 7

[0233] 8 mg of 3-hydroxypropionic acid, 9 mg of vitamin C, 9 mg of vitamin E, 200 mg of lactose, and 200 mg of galactooligosaccharide according to the above Manufacturing Example 1 are mixed, granulated using a fluidized bed dryer, and 5 mg of sugar ester is added to prepare a tablet composition. 500 mg of the above tablet composition is pressed into tablets to prepare tablets.

[0234]

[0235] Formulation Example 8

[0236] A soft capsule filling liquid is prepared by mixing 8 mg of 3-hydroxypropionic acid, 9 mg of vitamin C, 9 mg of vitamin E, 10 mg of hydrogenated vegetable oil, and 9 mg of lecithin according to the above Manufacturing Example 1. Separately, a soft capsule sheet is prepared by mixing 65 wt% of gelatin, 25 wt% of glycerin, and 10 wt% of sorbitol solution. 400 mg of the above soft capsule filling liquid is filled into each capsule to prepare a soft capsule.

[0237]

[0238] Formulation Example 9

[0239] 8 mg of 3-hydroxypropionic acid, 9 mg of vitamin C, 9 mg of vitamin E, 500 mg of starch, and 200 mg of anhydrous crystalline glucose according to the above manufacturing example 1 are mixed, formed into granules using a fluidized bed granulator, and then filled into a bag to manufacture a granule preparation.

[0240]

[0241] Formulation Example 10

[0242] A drink composition is prepared by mixing 8 mg of 3-hydroxypropionic acid, 9 mg of vitamin C, 9 mg of vitamin E, 0.7 g of citric acid, 10 g of glucose, and 25 g of liquid oligosaccharide according to the above manufacturing example 1, and then adding 300 ml of purified water. 200 ml of the drink composition is filled into bottles and sterilized at 130°C for about 5 seconds to prepare a drink.

[0243]

[0244] Formulation Example 11

[0245] An injection is prepared by mixing 30 mg of 3-hydroxypropionic acid according to the above manufacturing example 1, an appropriate amount of sterile distilled water for injection, and an appropriate amount of a pH regulator.

[0246]

[0247] Although the present invention has been described above through limited embodiments, the present invention is not limited thereto, and it is obvious that various modifications and variations are possible within the scope of the technical idea of ​​the present invention and the equivalent scope of the patent claims to be described below by a person having ordinary skill in the art to which the present invention pertains.

Claims

A cosmetic composition for preventing, alleviating or improving hair loss, comprising 1.3-hydroxypropionic acid or a derivative thereof as an active ingredient.

2. In paragraph 1, The above cosmetic composition is a cosmetic composition for preventing, alleviating or improving hair loss, which inhibits the action of TGF-β1 factor secreted from hair follicle cells.

3. In paragraph 1, The above cosmetic composition is a cosmetic composition for preventing, alleviating or improving hair loss, which inhibits the activity of 5α-reductase, which produces dihydrotestosterone.

4. In paragraph 1, A cosmetic composition for preventing, alleviating or improving hair loss, comprising 0.01 wt% to 1 wt% of the effective ingredient based on the total weight of the composition.

5. In paragraph 1, A cosmetic composition for preventing, alleviating or improving hair loss, wherein the above effective ingredient has a radioactive carbon isotope content of 20 pMC (percent modern carbon) or more as measured according to ASTM D6866-21 and a biocarbon content of 20 wt% or more.

6. In paragraph 1, A cosmetic composition for preventing, alleviating or improving hair loss, wherein the cosmetic composition further comprises a physiologically acceptable medium.

7. In paragraph 1, The above cosmetic composition is a cosmetic composition for hair or scalp, for preventing, alleviating or improving hair loss.

8. In paragraph 1, The above cosmetic composition has a formulation that is a hair shampoo, hair rinse, hair tonic, hair treatment, scalp treatment, hair lotion, hair cream, hair spray, hair foam, hair gel, hair pack, hair aerosol, hair dye, balm, powder, solid soap, or liquid soap, and is a cosmetic composition for preventing, alleviating, or improving hair loss. A pharmaceutical composition for preventing or treating hair loss, comprising 9.3-hydroxypropionic acid or a derivative thereof as an active ingredient.

10. In paragraph 9, The above pharmaceutical composition is a pharmaceutical composition for preventing or treating hair loss that inhibits the action of TGF-β1 factor secreted from hair follicle cells.

11. In paragraph 9, The above pharmaceutical composition is a pharmaceutical composition for preventing or treating hair loss, which inhibits the activity of 5α-reductase, which produces dihydrotestosterone.

12. In paragraph 9, A pharmaceutical composition for preventing or treating hair loss, comprising 0.01 wt% to 1.5 wt% of the active ingredient based on the total weight of the composition.

13. In paragraph 9, A pharmaceutical composition for preventing or treating hair loss, wherein the above active ingredient has a radioactive carbon isotope content of 20 pMC (percent modern carbon) or more as measured according to ASTM D6866-21 standard and a biocarbon content of 20 wt% or more.

14. In paragraph 9, A pharmaceutical composition for preventing or treating hair loss, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

15. In paragraph 9, The above pharmaceutical composition is a pharmaceutical composition for preventing or treating hair loss, for oral or parenteral use.

16. Use of 3-hydroxypropionic acid or a derivative thereof for the manufacture of cosmetics for preventing, alleviating or improving hair loss or drugs for preventing or treating hair loss. A method for preventing, alleviating, improving, or treating hair loss using a cosmetic composition or pharmaceutical composition containing 17.3-hydroxypropionic acid or a derivative thereof as an active ingredient.

Images